APA (7th ed.) Citation

Meng J, Lister J, Vataire AL, Casciano R, & Dinet J. (2018). Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England. Dove Medical Press.

Chicago Style (17th ed.) Citation

Meng J, Lister J, Vataire AL, Casciano R, and Dinet J. Cost-effectiveness Comparison of Cabozantinib with Everolimus, Axitinib, and Nivolumab in the Treatment of Advanced Renal Cell Carcinoma Following the Failure of Prior Therapy in England. Dove Medical Press, 2018.

MLA (9th ed.) Citation

Meng J, et al. Cost-effectiveness Comparison of Cabozantinib with Everolimus, Axitinib, and Nivolumab in the Treatment of Advanced Renal Cell Carcinoma Following the Failure of Prior Therapy in England. Dove Medical Press, 2018.